EI
ABBV icon

Ethic Inc’s AbbVie ABBV Stock Holding History

Ethic Inc’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.6M Buy
80,720
+8,264
+11% +$1.83M 0.27% 63
2025
Q4 		$16.6M Buy
72,456
+3,141
+5% +$716K 0.25% 68
2025
Q3 		$16M Buy
69,315
+3,535
+5% +$720K 0.26% 65
2025
Q2 		$12M Sell
65,780
-2,017
-3% -$375K 0.21% 92
2025
Q1 		$14M Sell
67,797
-29,888
-31% -$5.81M 0.28% 66
2024
Q4 		$17.4M Buy
97,685
+10,120
+12% +$1.86M 0.35% 45
2024
Q3 		$15.9M Sell
87,565
-7,114
-8% -$1.33M 0.4% 38
2024
Q2 		$16.2M Buy
94,679
+7,114
+8% +$1.18M 0.38% 43
2024
Q1 		$15.9M Buy
87,565
+48,995
+127% +$8.44M 0.4% 38
2023
Q4 		$5.98M Buy
38,570
+3,574
+10% +$521K 0.18% 130
2023
Q3 		$5.22M Buy
34,996
+2,683
+8% +$394K 0.18% 128
2023
Q2 		$4.35M Sell
32,313
-3,888
-11% -$570K 0.16% 150
2023
Q1 		$5.77M Sell
36,201
-552
-2% -$84.4K 0.23% 100
2022
Q4 		$5.94M Sell
36,753
-15,719
-30% -$2.41M 0.32% 70
2022
Q3 		$7.04M Buy
52,472
+3,837
+8% +$551K 0.48% 31
2022
Q2 		$7.45M Buy
48,635
+16,766
+53% +$2.56M 0.52% 25
2022
Q1 		$5.17M Buy
31,869
+12,163
+62% +$1.77M 0.36% 60
2021
Q4 		$2.67M Buy
19,706
+755
+4% +$89.2K 0.21% 119
2021
Q3 		$2.04M Buy
18,951
+10,064
+113% +$1.15M 0.21% 125
2021
Q2 		$1M Sell
8,887
-3,471
-28% -$391K 0.12% 208
2021
Q1 		$1.34M Sell
12,358
-4,016
-25% -$430K 0.24% 103
2020
Q4 		$1.75M Sell
16,374
-3,060
-16% -$294K 0.46% 37
2020
Q3 		$1.7M Buy
19,434
+4,374
+29% +$412K 0.65% 30
2020
Q2 		$1.48M Buy
15,060
+4,264
+39% +$375K 0.84% 21
2020
Q1 		$823K Buy
10,796
+760
+8% +$64.7K 0.69% 35
2019
Q4 		$889K Buy
+10,036
New +$833K 0.65% 36

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ethic Inc's ABBV Position: Q1 2026 in Review

Ethic Inc increased its AbbVie (ABBV) stake by 11% in Q1 2026, buying an estimated $1.83M and bringing the position to 80,720 shares worth $17.6M. The position accounts for 0.27% of the portfolio, ranked #63.

Ethic Inc first reported a position in ABBV in Q4 2019 and has held it in 26 quarters since. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Ethic Inc held 80,720 shares of AbbVie worth $17.6M as of Q1 2026.
  • Ethic Inc bought 8,264 AbbVie shares in Q1 2026, an estimated $1.83M.
  • AbbVie made up 0.27% of Ethic Inc's portfolio in Q1 2026, its #63 holding.
  • Ethic Inc first reported a position in AbbVie in Q4 2019 and has held it in 26 quarters since.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Ethic Inc's 13F filing for Q1 2026, filed 27 Apr 2026.